Kabigef 250 Tablet
Gefitinib
250mg
Fresenius Kabi pharmaceuticals
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 305.70 NPR |
Indications
Kabigef 250 Tablet is used for:
Non-small Cell Lung Cancer
Adult Dose
Oral
Locally advanced or metastatic non-small cell lung carcinoma
Adult: 250 mg once daily.
Child Dose
Renal Dose
Administration
Film-coated tab: May be taken with or without food. May also be dispersed in ½ glass of plain, non-carbonated water. No other liqd should be used. Drop the tab in water & stir w/o crushing until it disperses (approx 10 min). Drink immediately. Rinse glass w/ another ½ glass of water & drink. Dispersed liqd may also be administered via NG tube.
Contra Indications
Hypersensitivity. Lactation.
Precautions
Patients w/ concurrent idiopathic pulmonary fibrosis, acute onset or worsening pulmonary or eye symptoms. Renal and hepatic impairment. Pregnancy. Monitoring Parameters Monitor liver function, prothrombin time or INR frequently.
Lactation
Unknown if distributed in human breast milk; not recommended
Pregnancy-Lactation
Interactions
Concomitant use w/ CYP3A4 inducers (e.g. rifampicin, phenytoin, carbamazepine, barbiturates) may reduce serum gefitinib levels. Plasma concentrations may be increased w/ potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole). Increased INR or bleeding events w/ warfarin. May increase plasma levels of metoprolol. May exacerbate vinorelbine-induced neutropenia. Decreased plasma levels and potential reduction in efficacy w/ drugs that affect gastric pH (e.g. PPIs, H2-receptor antagonists).
Adverse Effects
Side effects of Gefitinib :
>10%
Skin reactions, all grades (47%),Diarrhea, all grades (29%),Decreased appetite, all grades (17%),Vomiting, all grades (14%),Increased ALT, all grades (11.4%)
1-10%
Increased AST, all grades (7.9%),Stomatitis, all grades (7%),Conjunctivitis, blepharitis, and dry eye (6.7%),Conjunctivitis/blepharitis/dry eye (6%),Increased ALT, grades 3-4 (5.1%),Nail disorders, all grades (5%),Diarrhea, grades 3-4 (3%),Increased AST, grades 3-4 (3%),Increased bilirubin, all grades (2.7%),Decreased appetite, grades 2-3 (2.3%),Skin reactions, grades 3-4 (2%),Interstitial lung disease, all grades (1.3%),Vomiting, grades 3-4 (1.2%)
<1%
Interstitial lung disease, grades 3-4 (0.7%),Increased bilirubin, grades 3-4 (0.7%),Stomatitis, all grades (0.3%),Corneal erosion and aberrant eyelash growth (0.2%),Nail disorders, grades 3-4 (0.1%),Gastrointestinal perforation (0.1%),Ocular keratitis (0.1%),Erythema multiforme and dermatitis bullous (0.08%),Fatal hepatoxicity (0.04%)
Mechanism of Action
Gefitinib is a synthetic anilinoquinazoline which inhibits the intracellular phosphorylation of numerous tyrosine kinases associated w/ transmembrane cell surface receptors found on both normal and cancer cells, including epidermal growth factor receptor (EGFR) tyrosine kinase. Tyrosine kinase activity appears to be essentially important to cell proliferation and survival.
Note
Kabigef 250 250mg Tablet manufactured by Fresenius Kabi pharmaceuticals. Its generic name is Gefitinib. Kabigef 250 is availble in Nepal.
Farmaco Nepal drug index information on Kabigef 250 Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.